Cephalon's Long Shot Falls Short

Cephalon (Nasdaq: CEPH  ) tried and failed yesterday to convince an FDA advisory panel to approve broader use of its lead pain drug, Fentora.

Fentora is already approved as a treatment for cancer patients who have become unresponsive to other opioid pain medications, to which they can develop a tolerance over time. In a 17-to-3 vote, the FDA advisory panel recommended against approving the oral opioid fentanyl for the much broader chronic pain population because of the risk that it could be misused.

Cephalon already had to send out a dear doctor letter regarding Fentora last year after some patients misused it (or doctors wrongly prescribed it), resulting in serious injuries and death. Considering this fact, the advisory panel's negative opinion wasn't a big surprise. The FDA will likely reject Cephalon's proposed expanded label for the drug when it comes up for review in early September.

Fentora sales totaled $135 million last year, and $39 million in the first quarter this year. Cephalon hopes Fentora will replace sales of its other fentanyl painkiller Actiq, which started facing generic competition from Barr Pharmaceuticals (NYSE: BRL  ) in late 2006.

Considering that Fentora is already heavily used off-label, this negative panel recommendation and probable upcoming FDA rejection won't kill its sales growth. However, the limitation should prevent Fentora from earning anything as grand as the $572 million that Actiq brought in during its heyday in 2006.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 639769, ~/Articles/ArticleHandler.aspx, 10/26/2016 5:06:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
CEPH $0.00 Down +0.00 +0.00%
Cephalon, Inc. CAPS Rating: ****
BRL.DL $65.80 Down +0.00 +0.00%
Barr Pharmaceutica… CAPS Rating: ****